Effects of Matrix Metalloproteinase (MMP)-2 Polymorphisms on Responsiveness to Antihypertensive Therapy of Women with Hypertensive Disorders of Pregnancy

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 4, 2012, Pages 262-267

  Palei, Ana C T ^a   Sandrim, Valeria C ^b   Amaral, Lorena M ^c   Machado, Jackeline S R ^c   Cavalli, Ricardo C ^c   Lacchini, Riccardo ^c   Duarte, Geraldo ^c   Tanus Santos, Jose E ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Santa Casa of Belo Horizonte   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; HYDRALAZINE; METHYLDOPA; NIFEDIPINE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; DNA EXTRACTION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LOGISTIC MODELS; MATRIX METALLOPROTEINASE 2; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84866557864     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00905.x     Document Type: Article

References (37)

1. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;101:669-74.
2. Myers J, Mires G, Macleod M, Baker P In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005;45:258-63.
3. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 2006;8:1-20.
4. Visse R, Nagase H Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
5. Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H, et al. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003;24:53-64.
6. Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T, Yagel S Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am J Obstet Gynecol 1994;171:832-8.
7. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 2009;23:88-92.
8. Myers JE, Merchant SJ, Macleod M, Mires GJ, Baker PN, Davidge ST MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 2005;24:103-15.
9. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 2001;20:185-94.
10. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008;41:875-80.
11. Price SJ, Greaves DR, Watkins H Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-58.
12. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622-8.
13. Gai X, Zhang Z, Liang Y, Chen Z, Yang X, Hou J, et al. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin Chim Acta 2010;411:719-24.
14. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 2012;26:171-7.
15. Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P, et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004;25:688-93.
16. Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Duarte G, et al. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol 2012;92:217-21.
17. Podymow T, August P Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008;51:960-9.
18. Marcal DM, Rizzi E, Martins-Oliveira A, Ceron CS, Guimaraes DA, Gerlach RF, et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011;383:35-44.
19. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM, et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008;591:224-30.
20. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K, et al. The effect of Ca2 + channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 2004;17:273-6.
21. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
22. Lacchini R, Metzger IF, Luizon M, Ishizawa M, Tanus-Santos JE Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol 2011;29:649-55.
23. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2010;10:40-5.
24. Stephens M, Scheet P Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005;76:449-62.
25. Stephens M, Smith NJ, Donnelly P A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
26. Broughton Pipkin F Risk factors for preeclampsia. N Engl J Med 2001;344:925-6.
27. Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension. Am J Hypertens 2005;18:325-9.
28. Jacob-Ferreira AL, Lacchini R, Gerlach RF, Passos CJ, Barbosa F Jr, Tanus-Santos JE A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. Sci Total Environ 2011;409:4242-6.
29. Marson BP, Lacchini R, Belo V, Dickel S, da Costa BP, Poli de Figueiredo CE, et al. Matrix Metalloproteinase (MMP)-2 Genetic Variants Modify the Circulating MMP-2 Levels in End-Stage Kidney Disease. Am J Nephrol 2012;35:209-15.
30. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004;383:413-8.
31. Ceron CS, Rizzi E, Guimaraes DA, Martins-Oliveira A, Cau SB, Ramos J, et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol 2012;31:261-70.
32. Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C, et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011;109:130-7.
33. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012;413:656-62.
34. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47:117-22.
35. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010;160:77-87.
36. Metzger IF, Luizon MR, Lacchini R, Tanus-Santos JE Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects. DNA Cell Biol 2012;31:504-10.
37. Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Lacchini R, et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 2011; doi:10.1038/tpj.2011.31[Epub ahead of print].